Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
230 stopped studies mapped to Breast Carcinoma by Gene Expression Profile and descendants · 97% state a reason
Over the 230 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03621982 | Study of ADCT-301 in Patients With Selected Advanced Solid Tumors | Phase 1 | terminated | Aug 9, 2018 | ADC Therapeutics S.A. | Cami in combination with pembrolizumab in solid tumors showed signals of immunomodulatory activity.… | Other (stated, no rule matched) |
| NCT04927884 | A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast… | Phase 1 / Phase 2 | terminated | Jun 16, 2021 | ImmunityBio, Inc. | low enrollment | Enrollment / accrual |
| NCT03199040 | Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple… | Phase 1 | terminated | Jun 26, 2017 | Washington University School of Medicine | Drugs/equipment unavailable and insufficient funding | Funding |
| NCT04726332 | Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors… | Phase 1 | terminated | Jan 27, 2021 | Exelixis | Business reasons | Sponsor / business decision |
| NCT06057636 | Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study | N/A | withdrawn | Sep 28, 2023 | The University of Tennessee, Knoxville | Unable to recruit participants | Enrollment / accrual |
| NCT05134194 | A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy… | Phase 3 | terminated | Nov 24, 2021 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Sponsor R \& D Strategy Adjustment\] | Sponsor / business decision |
| NCT03361800 | Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage… | Early Phase 1 | terminated | Dec 5, 2017 | UNC Lineberger Comprehensive Cancer Center | Funding withdrawn. | Funding |
| NCT04691375 | A Study of PY314 in Subjects With Advanced Solid Tumors | Phase 1 | terminated | Dec 31, 2020 | Ikena Oncology | Sponsor business decision. | Sponsor / business decision |
| NCT03709082 | Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2… | Phase 1 / Phase 2 | terminated | Oct 17, 2018 | University of Kansas Medical Center | Low accrual | Enrollment / accrual |
| NCT05474690 | A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of… | Phase 3 | withdrawn | Jul 26, 2022 | Henan Cancer Hospital | The new treatment plan for HER2 positive breast cancer has entered the diagnosis and treatment… | Other (stated, no rule matched) |
| NCT04461600 | A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast…(TENACITY) | Phase 2 | terminated | Jul 8, 2020 | Ayala Pharmaceuticals, Inc, | Sponsor's decision | Sponsor / business decision |
| NCT04025216 | A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers | Phase 1 | terminated | Jul 18, 2019 | Kite, A Gilead Company | The sponsor finds the risk/benefit analysis unfavorable and has terminated the study. | Other (stated, no rule matched) |
| NCT03992131 | A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants… | Phase 1 / Phase 2 | terminated | Jun 20, 2019 | pharmaand GmbH | Due to a change in development priorities, no further clinical development of the lucitanib plus… | Other (stated, no rule matched) |
| NCT04244552 | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | Phase 1 | terminated | Jan 28, 2020 | Atreca, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT04690855 | A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative…(TARA) | Phase 2 | terminated | Dec 31, 2020 | Mylin A. Torres, MD | This study has been terminated due to Lack of Accrual. | Enrollment / accrual |
| NCT03861403 | A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus… | Phase 1 | terminated | Mar 4, 2019 | Leap Therapeutics, Inc. | Product development discontinued unrelated to safety. | Safety / toxicity |
| NCT02963363 | Adapted Physical Activity for Breast Cancer HER2 Positive Patient(APACAN2) | N/A | terminated | Nov 15, 2016 | Centre Jean Perrin | Insufficient recruitment | Enrollment / accrual |
| NCT04602117 | ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine… | Phase 1 | withdrawn | Oct 26, 2020 | QuantumLeap Healthcare Collaborative | Study withdrawn as scientific interest in pursuing the SYD985+Paclitaxel combination has diminished. | Other (stated, no rule matched) |
| NCT01873833 | Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating… | Phase 2 | terminated | Jun 10, 2013 | University of Southern California | Insufficient accrual | Enrollment / accrual |
| NCT04139993 | RBX7455 Before Surgery for the Treatment of Operable Breast Cancer | Phase 1 | terminated | Oct 25, 2019 | Mayo Clinic | poor accrual | Enrollment / accrual |
| NCT05371860 | Radiation Omission in Patients With HER2 Overexpressing Tumors With Pathologic Complete… | Phase 2 | withdrawn | May 12, 2022 | Armando Giuliano | PI voluntarily closed the study. Will be reopened as a national cooperative group trial. | Other (stated, no rule matched) |
| NCT04106167 | Long-term, Non-interventional, Observational Study Following Treatment With Fate… | — | terminated | Sep 26, 2019 | Fate Therapeutics | This study was terminated by the Sponsor. | Other (stated, no rule matched) |
| NCT04441099 | NBE-002 in Patients With Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Jun 22, 2020 | NBE-Therapeutics AG | End of Program | Other (stated, no rule matched) |
| NCT04185311 | Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating… | Phase 1 | terminated | Dec 4, 2019 | Jonsson Comprehensive Cancer Center | enrollment | Enrollment / accrual |
| NCT01712815 | PET/CT in Evaluating Response to Chemotherapy in Patients With Breast Cancer | N/A | terminated | Oct 24, 2012 | University of Southern California | Insufficient accrual | Enrollment / accrual |
| NCT04639245 | Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous… | Phase 1 / Phase 2 | terminated | Nov 20, 2020 | Fred Hutchinson Cancer Center | Terminated due to slow accrual. | Enrollment / accrual |
| NCT03576131 | GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors | Phase 1 / Phase 2 | terminated | Jul 3, 2018 | Genmab | Sponsor decision | Sponsor / business decision |
| NCT04424641 | A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid… | Phase 1 / Phase 2 | terminated | Jun 11, 2020 | Genmab | Study was terminated due to MTD was reached | Other (stated, no rule matched) |
| NCT05809895 | Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With…(AdvanTIG-211) | Phase 2 | withdrawn | Apr 12, 2023 | Novartis Pharmaceuticals | Business decision, not driven by safety concerns; no new safety signals have been observed in the… | Safety / toxicity |
| NCT05255666 | Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer… | Phase 2 | withdrawn | Feb 24, 2022 | Washington University School of Medicine | No drug | Other (stated, no rule matched) |
| NCT04348916 | Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With… | Phase 1 | terminated | Apr 16, 2020 | Oncorus, Inc. | Terminated due to Oncorus portfolio reprioritization | Sponsor / business decision |
| NCT05774886 | Implantable Microdevice for TNBC - Pilot Study | Phase 1 | withdrawn | Mar 20, 2023 | Dana-Farber Cancer Institute | On hold | Other (stated, no rule matched) |
| NCT04335006 | A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus… | Phase 3 | terminated | Apr 6, 2020 | Jiangsu HengRui Medicine Co., Ltd. | Sponsor R \& D Strategy Adjustment | Sponsor / business decision |
| NCT05368506 | ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian… | Early Phase 1 | withdrawn | May 10, 2022 | OHSU Knight Cancer Institute | PI discretion | Other (stated, no rule matched) |
| NCT03002103 | A Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel… | Phase 3 | suspended | Dec 23, 2016 | SynCore Biotechnology Co., Ltd. | study design reconsideration | Other (stated, no rule matched) |
| NCT04650451 | Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects… | Phase 1 | suspended | Dec 2, 2020 | Bellicum Pharmaceuticals | Due to a Dose Limiting Toxicity in another sister trial with same technology. | Safety / toxicity |
| NCT04489940 | Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative… | Phase 2 | terminated | Jul 28, 2020 | EMD Serono Research & Development Institute, Inc. | The study was prematurely discontinued by the sponsor due to probability of success which was too… | Enrollment / accrual |
| NCT03435640 | REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With…(REVEAL) | Phase 1 / Phase 2 | terminated | Feb 19, 2018 | Nektar Therapeutics | Based on the overall results from the Phase 1 part of the study the sponsor decided to end the… | Safety / toxicity |
| NCT02834247 | A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid… | Phase 1 | terminated | Jul 15, 2016 | Calithera Biosciences, Inc | Insufficient efficacy of drug; no safety concern | Safety / toxicity |
| NCT03982173 | Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and…(MATILDA) | Phase 2 | withdrawn | Jun 11, 2019 | Gustave Roussy, Cancer Campus, Grand Paris | Similar clinical trials showed not very encouraging results, which made us decide, after several… | Other (stated, no rule matched) |
| NCT04249167 | Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple… | Early Phase 1 | withdrawn | Jan 30, 2020 | Mayo Clinic | study was dropped | Other (stated, no rule matched) |
| NCT04291950 | Epigenetics of TNBC in Overweight and Obese Hispanic & Non-Hispanic White Women | — | withdrawn | Mar 2, 2020 | University of Arizona | Principal investigator is moving to a new institution. Study is closing. | Investigator |
| NCT05233696 | Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive… | Phase 2 | withdrawn | Feb 10, 2022 | University of Colorado, Denver | Low Accrual | Enrollment / accrual |
| NCT04268693 | Bisphenol and Phthalate Exposures in Triple Negative Breast Cancer(EDC-TNBC) | — | withdrawn | Feb 13, 2020 | George Washington University | Study never initiated due to COVID pandemic, staffing changes | COVID-19 / pandemic |
| NCT05093387 | SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative… | Phase 1 | withdrawn | Oct 26, 2021 | Northwestern University | funding issues and pharmacy preparation for the drug | Funding |
| NCT02124902 | Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and… | Phase 2 | terminated | Apr 28, 2014 | Washington University School of Medicine | Insufficient funding/staff | Funding |
| NCT02474173 | Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer | Phase 1 | terminated | Jun 17, 2015 | National Cancer Institute (NCI) | Drug supply issues | Drug supply |
| NCT03579472 | M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast… | Phase 1 | terminated | Jul 6, 2018 | M.D. Anderson Cancer Center | Due to the fact that the sponsor decided not to move forward with the development of M7824 | Sponsor / business decision |
| NCT02706392 | Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies | Phase 1 | terminated | Mar 11, 2016 | Fred Hutchinson Cancer Center | Terminated due to slow accruals. | Enrollment / accrual |
| NCT03750240 | Metabolic Sodium MRI to Assess Early Response of Breast Cancer to Neoadjuvant Chemotherapy | N/A | terminated | Nov 21, 2018 | NYU Langone Health | technical difficulties for scans on the research MRI system | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jun 13, 2024source: clinicaltrials